Ratings Raia Drogasil S.A.

Equities

RADL3

BRRADLACNOR0

Market Closed - Sao Paulo Other stock markets 04:07:48 2024-04-26 pm EDT			5-day change	1st Jan Change
25.62 ^BRL	+2.69%		+0.67%	-12.86%

Mar. 06	Transcript : Raia Drogasil S.A., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 05	Raia Drogasil S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's profit outlook over the next few years is a strong asset.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company benefits from high valuations in earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RAIA DROGASIL S.A.	-12.86%	8.28B		B
AIN HOLDINGS INC.	+32.95%	1.34B		-
QOL HOLDINGS CO., LTD.	+6.76%	427M		-
NIHON CHOUZAI CO.,LTD.	+5.93%	289M		-
SALUS, LJUBLJANA, D. D.	+10.56%	225M	-	-
GREEN CROSS HEALTH LIMITED	-8.26%	83.49M	-	-
MEDICAL IKKOU GROUP CO.,LTD.	+20.94%	59.81M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes